Rapport Therapeutics Files 8-K: Agreements & Equity
Ticker: RAPP · Form: 8-K · Filed: Jun 10, 2024 · CIK: 2012593
| Field | Detail |
|---|---|
| Company | Rapport Therapeutics, Inc. (RAPP) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $17.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-securities, corporate-filing
TL;DR
Rapport Therapeutics filed an 8-K detailing a material agreement, equity sales, and corporate changes.
AI Summary
On June 6, 2024, Rapport Therapeutics, Inc. entered into a material definitive agreement related to its business operations. The company also reported on unregistered sales of equity securities and amendments to its articles of incorporation or bylaws. This filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions and potential financial events for Rapport Therapeutics, Inc., which could impact its stock value and future strategic direction.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can carry inherent risks and require careful investor scrutiny.
Key Players & Entities
- Rapport Therapeutics, Inc. (company) — Registrant
- June 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-42121 (company_id) — Commission File Number
- 88-0724208 (tax_id) — I.R.S. Employer Identification No.
- 1325 Boylston Street, Suite 401 Boston, MA 02215 (address) — Principal executive offices
- (857) 321-8020 (phone_number) — Registrant's telephone number
FAQ
What type of material definitive agreement did Rapport Therapeutics, Inc. enter into?
The filing states that Rapport Therapeutics, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in this summary.
What is the significance of the 'Unregistered Sales of Equity Securities' item?
This indicates that the company has sold equity securities that were not registered with the SEC, which may have specific implications for the purchasers and the company.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 6, 2024.
Where are Rapport Therapeutics, Inc.'s principal executive offices located?
Rapport Therapeutics, Inc.'s principal executive offices are located at 1325 Boylston Street, Suite 401, Boston, MA 02215.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 1,405 words · 6 min read · ~5 pages · Grade level 12.4 · Accepted 2024-06-10 16:09:27
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share RAPP The Nasdaq
- $17.00 — initial public offering (IPO) price of $17.00 per share, through a private placement
Filing Documents
- d60139d8k.htm (8-K) — 26KB
- d60139dex31.htm (EX-3.1) — 30KB
- d60139dex32.htm (EX-3.2) — 119KB
- d60139dex101.htm (EX-10.1) — 244KB
- 0001193125-24-158327.txt ( ) — 420KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 3.1 Third Amended and Restated Certificate of Incorporation of Rapport Therapeutics, Inc. 3.2 Amended and Restated Bylaws of Rapport Therapeutics, Inc. 10.1 Form of Stock Purchase Agreement, by and among the Company and the Purchasers. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rapport Therapeutics, Inc. Date: June 10, 2024 By: /s/ Abraham N. Ceesay Abraham N. Ceesay, M.B.A. Chief Executive Officer and Director